Download Files:
Milademetan (tosylate hydrate)
$580 – $5,600
Products Details
Product Description
– Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis[1][2].
Web ID
– HY-101266B
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C37H44Cl2FN5O8S
References
– [1]ARYL SULFONOHYDRAZIDES. WO 2017069289 A1.|[2]M.M. Gounder, et al. Milademetan, an oral MDM2 inhibitor, in well-differentiated/dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas. European Journal of Cancer 138S2 (2020) S1–S62.|[3]Li, Yangbing, et al. Development of novel PROTAC Small-Molecule Degraders of MDM2 Protein and Peptidomimetic Inhibitors Targeting WDR5-MLL1 Protein-Protein Interaction.|[4]Viktor Arnhold, et al. Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma. ncotarget. 2018 Jan 5; 9(2): 2304–2319.
CAS Number
– 2095625-97-9
Molecular Weight
– 808.74
Compound Purity
– 98.21
SMILES
– CC1=CC=C(S(=O)(O)=O)C=C1.O=C2NC3=CC(Cl)=CC=C3[C@]24C5(N[C@H]([C@@H]4C6=CC=NC(Cl)=C6F)C(N[C@@H]7CC[C@H](OC7)C(N)=O)=O)CCC(C)(CC5)C.[H]O[H]
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 50 mg/mL (ultrasonic)
Target
– Apoptosis;E1/E2/E3 Enzyme;MDM-2/p53
Pathway
– Apoptosis;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
